Previous 10 | Next 10 |
Esperion Therapeutics, Inc. (ESPR) Q1 2021 Earnings Conference Call May 4, 2021 4:30 PM ET Company Participants Benjamin Church - Head, Corporate Communications & IR Timothy Mayleben - President and Chief Executive Officer Sheldon Koenig - Chief Operating Officer Richard Bartram - Chief F...
Image source: The Motley Fool. Esperion Therapeutics Inc (NASDAQ: ESPR) Q1 2021 Earnings Call May 4, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Esperion Therapeutics Inc (ESPR) Q1 2021 Earnings Call Transcript ...
The following slide deck was published by Esperion Therapeutics, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Esperion Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
Esperion Therapeutics (ESPR): Q1 GAAP EPS of -$3.50 misses by $0.77.Revenue of $8M (+344.4% Y/Y) misses by $11.93M.FY 2021 guidance: Research and development expenses for the are expected to be $120 million to $130 million; selling, general and administrative expenses are expected to be $200 ...
– U.S. Product Revenue of $6.4 Million, Growing Demand Offset by Lower Net Price – – Prescriptions Grew 46% Sequentially; More Than 35,000 Patients now on NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tab...
– First-of-its-kind outcomes trial designed to assess cardiovascular risk reduction in patients with documented intolerance to statin therapy – – Nearly half of trial participants are women, a significantly higher proportion than have been included in any ot...
Esperion Therapeutics (ESPR) has signed a new licensing agreement granting the exclusive rights to Daiichi Sankyo Company (DSKYF) to commercialize bempedoic acid and the bempedoic acid/ezetimibe combination tablet in additional countries.The deal allows Daiichi Sankyo to commercialize th...
ANN ARBOR, Mich., April 26, 2021 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced that an investor group led by Oberland Capital Management LLC (Oberland Capital) agreed to provide the third and final tranche of funding under the revenue-based funding agreement total...
– Esperion to Receive $30.0 Million Upfront and Up to $175.0 Million in Milestone Payments – – Milestones from Partnership with Daiichi Sankyo Group Now Total Up to $1.1 Billion – – Demonstrates Daiichi Sankyo Group...
ANN ARBOR, Mich., April 12, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2021 financial results after the close of the U.S. financial markets on Tuesday, May 4, 2021. Following the release, company management will host a webcast and co...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...